This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Early Recognition + Earlier Intervention = Slowing the Progression in Mild Cognitive Impairment / Early Alzheimer’s
Breaking Ground: The Latest Data on AD Disease-Modifying Therapies
Media formats available:
Details
Presenters
Comments
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Professor Sir John Hardy
Chair, Molecular Biology of Neurological Disease
Department of Neurodegenerative Diseases University College London
London, UKNo relevant financial relationships have been reported at this time.
Faculty:
Marwan N. Sabbagh, MD, FAAN
Vice Chairman for Research
Professor of Neurology
Barrow Neurological Institute
Phoenix, AZDr. Sabbagh has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Abbvie, Anavex, Cognito Therapeutics, Eisai, GSK, KeiferRx, Lilly, NeuroTherapia, Novo Nordisk, Prothena, Roche-Genentech, Signant Health, Synaptogenix
Ownership: Alzheon, Athira, Lighthouse Pharmaceuticals, NeuroReserve, NeuroTau, Optimal Cognitive Health Company, Reservoir Neuroscience, Seq BioMarque, TransDermix, uMethod Health, VersanumReviewers/Content Planners/Authors:
- Jennifer Brutsche has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Tim Person has nothing to disclose.
- Canan Schumann, PharmD, PhD, has nothing to disclose.
- Rosanne Strauss, PharmD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Apply clinically relevant tools to assess the subtle signs and symptoms of MCI to facilitate an earlier MCI diagnosis
- Tailor communication strategies to each community of patients to overcome implicit bias and health disparities, and to achieve optimal health outcomes and health equity
- Evaluate the latest FDA-approved treatments used to manage MCI during the early stages of AD, comparing their safety, efficacy, and impact on patient care strategies
- Develop treatment plans for patients diagnosed with mild cognitive impairment or the mild dementia stage of Alzheimer’s disease
Target Audience
This activity is designed to meet the educational needs of Neurologists and Primary Care Physicians, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with mild cognitive impairment or the mild dementia stage of Alzheimer’s.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until July 25, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity. 
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hours/0.1 CEUs of pharmacy contact hours.The Universal Activity Number for this program is JA0006235-0000-24-072-H01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Commercial Support
This activity is supported by an independent educational grant from Eisai, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of TotalCME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
